CO6781467A2 - Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak - Google Patents

Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak

Info

Publication number
CO6781467A2
CO6781467A2 CO13117486A CO13117486A CO6781467A2 CO 6781467 A2 CO6781467 A2 CO 6781467A2 CO 13117486 A CO13117486 A CO 13117486A CO 13117486 A CO13117486 A CO 13117486A CO 6781467 A2 CO6781467 A2 CO 6781467A2
Authority
CO
Colombia
Prior art keywords
imidazo
pyridazine
pyridine derivatives
jak inhibitors
jak
Prior art date
Application number
CO13117486A
Other languages
English (en)
Inventor
Rodriguez Jacob Gonzalez
Juan Bernat Vidal
Gispert Laura Vidal
TAÑA Jordi BACH
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43585650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6781467(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of CO6781467A2 publication Critical patent/CO6781467A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Se describen nuevos derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina que tienen la estructura química de fórmula (I); así como un procedimiento para su preparación, composiciones farmacéuticas que los comprenden y su uso en terapia como inhibidores de quinasas Janus (JAK).
CO13117486A 2010-11-26 2013-05-10 Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak CO6781467A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20100382318 EP2463289A1 (en) 2010-11-26 2010-11-26 Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US201161436212P 2011-01-26 2011-01-26

Publications (1)

Publication Number Publication Date
CO6781467A2 true CO6781467A2 (es) 2013-10-31

Family

ID=43585650

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13117486A CO6781467A2 (es) 2010-11-26 2013-05-10 Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak

Country Status (22)

Country Link
US (1) US9133200B2 (es)
EP (2) EP2463289A1 (es)
JP (1) JP5809704B2 (es)
KR (1) KR20140004637A (es)
CN (1) CN103228654A (es)
AR (1) AR087328A1 (es)
AU (1) AU2011334146A1 (es)
BR (1) BR112013012965A2 (es)
CA (1) CA2815029A1 (es)
CL (1) CL2013001464A1 (es)
CO (1) CO6781467A2 (es)
CR (1) CR20130210A (es)
EA (1) EA201300620A1 (es)
GT (1) GT201300137A (es)
IL (1) IL225232A0 (es)
MX (1) MX2013005257A (es)
NZ (1) NZ608718A (es)
PE (1) PE20140390A1 (es)
SG (1) SG190042A1 (es)
TW (1) TW201236683A (es)
UY (1) UY33752A (es)
WO (1) WO2012069202A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2497792C (en) 2002-09-06 2014-08-05 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014074381A1 (en) * 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
CN103845726A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 克拉屈滨和乙酸格拉默的组合用于治疗多发性硬化的用途
CA2901427A1 (en) 2013-03-07 2014-09-12 Califia Bio, Inc. Mixed lineage kinase inhibitors and method of treatments
MX2015011627A (es) 2013-03-14 2016-05-16 Teva Pharma Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos.
US20140357557A1 (en) * 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
US11629124B2 (en) * 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
JP2021008407A (ja) * 2017-10-02 2021-01-28 武田薬品工業株式会社 複素環化合物
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
IL293469B2 (en) 2019-12-19 2024-04-01 Active Biotech Ab Compounds for the treatment of eye diseases are associated with increased blood vessel formation
AU2021288107A1 (en) 2020-06-12 2022-12-15 Incyte Corporation Imidazopyridazine compounds with activity as ALK2 inhibitors
EP4308122A1 (en) * 2021-03-15 2024-01-24 Chiesi Farmaceutici S.p.A. Heterocyclic derivatives as janus kinase inhibitors
WO2022194781A1 (en) * 2021-03-15 2022-09-22 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
CA3212256A1 (en) * 2021-03-16 2022-09-22 Juhyun Lee Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
US20240051957A1 (en) * 2021-03-16 2024-02-15 Hk Inno.N Corporation Crystalline form of heterocyclic compound as protein kinase inhibitor
WO2023133201A1 (en) * 2022-01-05 2023-07-13 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
WO2024052513A1 (en) * 2022-09-09 2024-03-14 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
WO2024052512A1 (en) * 2022-09-09 2024-03-14 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54128591A (en) 1978-03-25 1979-10-05 Kyowa Hakko Kogyo Co Ltd Cephalosporin analog
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ATE209938T1 (de) 1990-09-26 2001-12-15 Pharmachemie Bv Wirbelkammer-pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
HU215510B (hu) 1992-12-18 1999-01-28 Schering Corp. Inhalátor por alakú gyógyszerekhez
EP1547636A1 (en) 1995-04-14 2005-06-29 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
NZ502870A (en) 1995-06-21 2001-06-29 Asta Medica Ag Inhaler for powdered medicaments comprising a visual display device to indicate the discharge status of the inhaler
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
GB0206723D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel compounds
ATE381332T1 (de) 2002-05-02 2008-01-15 Merck & Co Inc Tyrosinkinase-hemmer
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PL2332940T3 (pl) 2004-03-30 2013-03-29 Vertex Pharma Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych
EP1598348A1 (en) * 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2572790C (en) 2004-07-16 2014-12-23 Laboratorios Almirall, S.A. Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
DE602005014382D1 (de) 2004-12-21 2009-06-18 Smithkline Beecham Corp 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
PL1846394T3 (pl) 2005-02-04 2012-04-30 Astrazeneca Ab Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
ES2296516B1 (es) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
EP2038279A2 (en) 2006-06-06 2009-03-25 Avigen, Inc. Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use
EP1900739A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
EP2063962A2 (en) * 2006-09-07 2009-06-03 Biogen Idec MA Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
CL2007002866A1 (es) 2006-10-04 2008-07-04 Pharmacopeia Inc Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
ATE542818T1 (de) 2006-10-11 2012-02-15 Amgen Inc Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
ES2302447B1 (es) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
RU2009120389A (ru) * 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
PL2121687T3 (pl) 2006-12-22 2016-03-31 Astex Therapeutics Ltd Pochodne amin tricyklicznych jako inhibitory białkowej kinazy tyrozynowej
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
UY31292A1 (es) 2007-08-14 2009-03-31 Imidazoles biciclicos fusionados
MX2010001824A (es) 2007-08-17 2010-04-21 Icagen Inc Heterociclos como moduladores de canal de potasio.
PL2212323T3 (pl) 2007-10-17 2013-01-31 Novartis Ag Pochodne imidazo[1,2-a]pirydyny użyteczne jako inhibitory ALK
JP2011500806A (ja) 2007-10-25 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2252618A1 (en) 2007-12-19 2010-11-24 Vertex Pharmaceuticals Incorporated PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS
AU2008345681A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-a] pyridine compounds
CN101970424B (zh) * 2008-01-22 2013-06-12 弗奈利斯（R&D）有限公司 具有检测点激酶1抑制活性的吲哚基吡啶酮衍生物
PT2247592E (pt) 2008-02-25 2011-11-03 Hoffmann La Roche Inibidores de pirrolpirazina-cinase
EP2300469B1 (en) * 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
US8518952B2 (en) 2008-08-06 2013-08-27 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
AR074870A1 (es) 2008-12-24 2011-02-16 Palau Pharma Sa Derivados de pirazolo (1,5-a ) piridina
WO2010094645A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
DK2493895T3 (en) 2009-10-29 2017-08-14 Vectura Ltd N-CONTRIBUTING HETEROYEER DERIVATIVES AS JAK3 KINase INHIBITORS
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors

Also Published As

Publication number Publication date
KR20140004637A (ko) 2014-01-13
MX2013005257A (es) 2014-02-06
WO2012069202A1 (en) 2012-05-31
AR087328A1 (es) 2014-03-19
US9133200B2 (en) 2015-09-15
UY33752A (es) 2012-05-31
CL2013001464A1 (es) 2013-09-06
BR112013012965A2 (pt) 2016-08-23
CA2815029A1 (en) 2012-05-31
SG190042A1 (en) 2013-06-28
CR20130210A (es) 2013-08-09
JP2014501724A (ja) 2014-01-23
TW201236683A (en) 2012-09-16
GT201300137A (es) 2014-04-03
PE20140390A1 (es) 2014-03-29
EP2643321A1 (en) 2013-10-02
JP5809704B2 (ja) 2015-11-11
AU2011334146A1 (en) 2013-04-04
EP2463289A1 (en) 2012-06-13
EA201300620A1 (ru) 2013-12-30
NZ608718A (en) 2015-04-24
IL225232A0 (en) 2013-06-27
US20130309200A1 (en) 2013-11-21
CN103228654A (zh) 2013-07-31

Similar Documents

Publication Publication Date Title
CO6781467A2 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
CR20120427A (es) Derivados de pirazol como inhibidores de jak
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
UY32239A (es) Nuevos derivados de (3-oxo)piridazin-4-ilurea
CR20130543A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20150175A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
CR20130617A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
BRPI1012697A2 (pt) derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
UY35087A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
UY32415A (es) NUEVOS DERIVADOS DE TETRAHIDROPIRAZOLO[3,4-c]ISOQUINOLIN-5-AMINA
UY30982A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones.
CU20100005A7 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP15015088A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CU20100250A7 (es) Compuestos pirazólicos 436
CU20100004A7 (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k

Legal Events

Date Code Title Description
FG Application granted